Abstract:Proceedings: AACR 101st Annual Meeting 2010‐‐ Apr 17‐21, 2010; Washington, DC There have been a lot studies focusing on EGFR mutation analysis in the patients of lung cancer especially in the patients with adenocarcinoma, for EGFR mutation has shown helpful in patient prognosis and therapeutic selection. Erlotinib and Gefitinib are playing increasing role in late stage adenocarcinoma of lung although it has not been listed as a first line treatment for advanced patients of Asian ethnic yet. However, the fact of a better respond rate to Erlotinib and Gefitinib and longer survival related to the mutant status of EGFR gene among Asian patients is encouraging the use for routine test of this gene in clinical service for lung cancer patients. Ninety two Chinese cancer patients were included into the study, from which 60 were lung cancer. The other cases were 11 supraclavicular lymph node biopsies and 21 tumor masses of different sites with differentiation diagnosis needed. EGFR mutation analysis was performed in DNA extracted from tumor tissue or biopsy samples. Overall mutation rate of EGFR was 42.39% (39/92) in whole patient group. The mutation rate in lung cancer was 46.67% (28/60) whereas it turned to 58.14% (25/43) when only looking at adenocarcinoma (56.10%, 23/41) and adenosquamous carcinoma (100%, 2/2). No mutation was found in squamous carcinoma, large cell carcinoma and poorly differentiated carcinoma. EGFR mutation analysis in the samples from Endobronchila Ultrasound-Guided Transbronchial Needle Aspiration (EBUS-TBNA) for mediastinal masses revealed an EGFR mutation rate of 42.86% (3/7), mimicking the mutation rate of lung cancer in our study. Forty eight percent of the EGFR mutation was located in exon 19 and 36% of the mutation in exon 21. Mutation of exon 19 seemed to be lower in the patient group older (35.71%, 5/14) than 58 year old (median age) than that in the patient group younger than 58 year old (58.82%, 10/17) (P=0.0581). In opposition, mutation rate of exon 21 appeared higher in the older group (64.29%, 9/14) than that in the younger patient group (23.53%, 4/17) (P=0.0800). The mutations in male patients were mainly located in exon 19 (71.43%, 10/14). And the mutation rate of exon 19 and 21 in female patients showed very close (43.47%, 10/23 for exon 19 and 47.83%, 11/23 for exon 21). Mutation rate of exon 20 was generally low but showed a higher rate in younger and female patients (17.65% and 13.04%). Mutation of supraclavicular lymph node was quite high (36.37%, 4/11) while mutation rate from variant site was low (20.00%, 4/20). One adenocarcinoma located in uterus muscle layer was demonstrated to possess an exon 19 mutation. All follow up analysis is in process. In conclusion, EGFR mutation analysis is a useful tool in defining patients suitable for EGFR TKI treatment as well as helpful in differentiation diagnosis in metastasis lesion. Mutation analysis in the samples derived from EBUS-TBNA is especially of important with clinical value. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 4669.

Table S1 from Genome-wide DNA Methylation Analysis Reveals <i>GABBR2</i> as a Novel Epigenetic Target for <i>EGFR</i> 19 Deletion Lung Adenocarcinoma with Induction Erlotinib Treatment

Table S3 from Genome-wide DNA Methylation Analysis Reveals GABBR2 As a Novel Epigenetic Target for EGFR 19 Deletion Lung Adenocarcinoma with Induction Erlotinib Treatment

Genome-Wide Dna Methylation Analysis Reveals Gabbr2 As A Novel Epigenetic Target for Egfr 19 Deletion Lung Adenocarcinoma with Induction Erlotinib Treatment

P3.02b-041 Genome-Wide Screen of DNA Methylation Changes Reveals GABBR2 As a Novel Potential Target for EGFR 19 Deletion Adenocarcinoma with Erlotinib: Topic: EGFR Biomarkers

PS01.80: Genome-Wide Screen of DNA Methylation Changes Reveals GABBR2 As a Novel Potential Target for EGFR 19 Deletion Adenocarcinoma with Erlotinib: Topic: Medical Oncology.

Genome-wide Screen of DNA Methylation Study in Stage IIIa (N2) EGFR 19 Deletion Adenocarcinoma with Erlotinib Treatment.

Genome-wide Methylation Profiling Reveals Differentially Methylated Genes in Blood DNA of Small-Cell Lung Cancer Patients

An integrated epigenomic-transcriptomic landscape of lung cancer reveals novel methylation driver genes of diagnostic and therapeutic relevance

Supplementary Tables from DNMT1–MicroRNA126 Epigenetic Circuit Contributes to Esophageal Squamous Cell Carcinoma Growth Via ADAM9–EGFR–AKT Signaling

Abstract 1611: DNA methylation co-operates with genomic alterations during non-small cell lung cancer evolution

Expression, DNA methylation pattern and transcription factor EPB41L3 in gastric cancer: a study of 262 cases

Combined Methylome and Transcriptome Analyses Reveals Potential Therapeutic Targets for EGFR Wild Type Lung Cancers with Low PD-L1 Expression

Identification of Tissue-Specific Gene Clusters Induced by DNA Demethylation in Lung Adenocarcinoma: More Than Germline Genes

Abstract 1679: Genome-wide Methylation Analysis in Barrett's Esophagus and Esophageal Adenocarcinoma

Supplementary Table 2 from DNA Methylation-Mediated Repression of miR-886-3p Predicts Poor Outcome of Human Small Cell Lung Cancer

Comprehensive analyses of genome-wide methylation and RNA epigenetics identify prognostic biomarkers, regulating the tumor immune microenvironment in lung adenocarcinoma.

Uncovering Driver DNA Methylation Events in Nonsmoking Early Stage Lung Adenocarcinoma.

Integrative Analysis of DNA Methylomes Reveals Novel Cell-Free Biomarkers in Lung Adenocarcinoma.

Whole DNA Methylome Profiling in Lung Cancer Cells Before and after Epithelial-to-mesenchymal Transition.

Pharmacologic inhibition of epigenetic modifications, coupled with gene expression profiling, reveals novel targets of aberrant DNA methylation and histone deacetylation in lung cancer

Abstract 4669: EGFR Gene Mutation Analysis in Chinese Lung Cancer Patients: Value for Differentiation Diagnostics and Therapeutics